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OBJECTIVE—The 5-5 homozygous CNDP1 (carnosinase) geno-
type is associated with a reduced risk of diabetic nephropathy.
We investigated whether this association is sex speciﬁc and
independent of susceptibility for type 2 diabetes.
RESEARCH DESIGN AND METHODS—Three separate
groups of 114, 90, and 66 patients with type 2 diabetes and
diabetic nephropathy were included in this study and compared
with 93 patients with type 2 diabetes for 15 years without
diabetic nephropathy and 472 population control subjects. The
diabetes control group was used to determine an association in
the three patient groups separately, and the population control
group was used to estimate the genotype risk [odds ratio (CI)] for
the population in a pooled analysis. The population control
subjects were also compared with 562 patients with type 2
diabetes without diabetic nephropathy to determine whether the
association was independent of type 2 diabetes. The CNDP1
genotype was determined by fragment analysis after PCR
ampliﬁcation.
RESULTS—The frequency of the 5-5 homozygous genotype was
28, 36, and 41% in the three diabetic nephropathy patient groups
and 43 and 42% in the diabetic and population control subjects,
respectively. The 5-5 homozygous genotype occurred signiﬁ-
cantly less frequently in women in all three patient groups
compared with diabetic control subjects. The genotype risk for
the population was estimated to be 0.5 (0.30–0.68) in women and
1.2 (0.77–1.69) in men. The 562 patients with type 2 diabetes
without diabetic nephropathy did not differ from the general
population (P  0.23).
CONCLUSIONS—This study suggests that the association be-
tween the CNDP1 gene and diabetic nephropathy is sex speciﬁc
and independent of susceptibility for type 2 diabetes. Diabetes
59:1555–1559, 2010
O
nly 20–40% of patients with type 1 or type 2
diabetes will develop diabetic nephropathy,
and if no signs of nephropathy are present in
the ﬁrst 15 years after diagnosis of diabetes, the
chance of ever developing nephropathy is small (1). Fur-
thermore, sibling studies show a strong familial compo-
nent for development of diabetic nephropathy (2,3), and
certain ethnic groups seem to be at a greater risk of
developing nephropathy (2,4). These ﬁndings suggest that
there is a genetic susceptibility component for diabetic
nephropathy.
Many genes are thought to be involved in diabetic
nephropathy (rev. in 5). One of the genes associated with
nephropathy in both patients with type 1 and type 2
diabetes is the CNDP1 gene, which encodes serum car-
nosinase (6). This was conﬁrmed in European Americans
with end-stage diabetic nephropathy due to type 2 diabetes
(7), but the association between diabetic nephropathy and
the CNDP1 gene could not be conﬁrmed in patients with
diabetic nephropathy due to type 1 diabetes (8,9) nor in
African Americans (7).
Patients with type 2 diabetes of Caucasian origin with
homozygosity for ﬁve leucine repeats in exon 2 demon-
strated a reduced susceptibility for developing diabetic
nephropathy compared with individuals with six to eight
repeats (6,7,10). With increasing numbers of leucine re-
peats, the secretion of serum carnosinase has been shown
to increase (11) and to lead to higher serum carnosinase
activity (4,6). Serum carnosinase degrades carnosines and
other histidine-containing dipeptides. Carnosines and re-
lated dipeptides are known for their reactive oxygen
scavenging effects (12), for degrading advanced glycation
end products (13), and for reducing the transforming
growth factor (TGF)-–induced synthesis of extracellular
matrix components (6).
Some genes involved in diabetic nephropathy have been
shown to have sex speciﬁc effects (14,15). For example,
the RANTES receptor gene (CCR5) is only associated with
diabetic nephropathy in men (14), and two single nucleo-
tide polymorphisms in the podocyte slit diaphragm gene
(ACTN4) were only associated with diabetic nephropathy
in women (15).
Therefore, we investigated whether the association be-
tween the CNDP1 gene and diabetic nephropathy due to
type 2 diabetes is sex speciﬁc. Furthermore, we studied
whether the association between diabetic nephropathy
and the CNDP1 gene is independent of the susceptibility
for type 2 diabetes itself.
From
1Pathology, Leiden University Medical Center, Leiden, the Netherlands;
2Nephrology, University Medical Center Groningen, Groningen, the Nether-
lands;
3Clinical Epidemiology, Leiden University Medical Center, Leiden,
the Netherlands; the
4Diabetes Centre, Isala Clinic, Zwolle, the Netherlands;
the
5Medical Research Group, Langerhans, Zwolle, the Netherlands;
6Social
Medicine, Academic Medical Center, Amsterdam, the Netherlands; the
7Department of Medical Statistics and Bioinformatics, Leiden University
Medical Center, the Netherlands;
8Internal Medicine, University Medical
Center Groningen, Groningen, the Netherlands; the
9Institute of Human
Genetics, Heidelberg, Germany; and
10ServiceXS, Leiden, the Netherlands.
Corresponding author: Antien L. Mooyaart, a.l.mooyaart@lumc.nl.
Received 16 September 2009 and accepted 8 March 2010. Published ahead of
print at http://diabetes.diabetesjournals.org on 23 March 2010. DOI:
10.2337/db09-1377.
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
BRIEF REPORT
diabetes.diabetesjournals.org DIABETES, VOL. 59, JUNE 2010 1555RESEARCH DESIGN AND METHODS
The institutional medical ethics committees of the participating hospitals
approved of the studies described below.
Case groups. For the ﬁrst case group, female and male Caucasian diabetic
patients with diabetic nephropathy from the case-control study of Janssen et
al. (6) were reassessed separately. Diabetic nephropathy was deﬁned as
diabetes with retinopathy with either macroalbuminuria or as being on
dialysis (because of diabetic nephropathy). The details of the recruitment of
this cohort are described elsewhere (6). In the present analysis, only 114
diabetic nephropathy patients with type 2 diabetes were included, and this
group will be referred to as diabetic nephropathy group 1.
For the second case group, diabetic nephropathy patients were selected
from the ZODIAC (Zwolle Outpatient Diabetes Project Integrating Available
Care) study (16). Diabetic nephropathy was deﬁned as having either an
estimated glomerular ﬁltration rate 60 ml/min/1.73 m
2 (17) in combination
with an albumin excretion 30 mg/l (18) or macroalbuminuria (300 mg/l) in
combination with retinopathy (19). ZODIAC was a cross-sectional single-
center study investigating only patients with type 2 diabetes, selected from a
population of 95% Caucasian origin. Patients were recruited from 61 general
practitioners from 1998 to 2000. In this study, 90 diabetic nephropathy patients
were identiﬁed, and these will be referred to as diabetic nephropathy group 2.
For the third group, diabetic nephropathy patients were selected out of a
total of 875 patients from the NECOSAD (Netherlands Cooperative Study on
the Adequacy of Dialysis) study (20). NECOSAD is a multicenter prospective
follow-up study of patients with end-stage renal disease who were included at
the start of dialysis, between 1997 and 2005. For the present analysis, only
patients with type 2 diabetes of Caucasian origin and end-stage renal disease
due to diabetic nephropathy were selected; 66 diabetic nephropathy patients
were included and are referred to as diabetic nephropathy group 3.
Control groups. The ﬁrst control group is a diabetic group, consisting of
Caucasian patients with type 2 diabetes without microalbuminuria for at least
15 years, in the absence of ACE inhibitor treatment (6,16). This control group
is referred to as diabetic non-nephropathy control subjects.
The second control group is a population control group selected from the
SUNSET (Surinamese in the Netherlands: Study on health and Ethnicity)
study, a population-based cross-sectional survey (21). In brief, between 2001
and 2003, a random sample of noninstitutionalized adults aged 35–60 years
was selected. In the present study, only the 472 white Dutch participants, of
whom the genotypic distribution was described in a previous report (4), are
used and referred to as population control subjects.
To investigate whether the association between diabetic nephropathy and
the CNDP1 gene is not due to susceptibility for type 2 diabetes, we addition-
ally studied 562 patients with type 2 diabetes without diabetic nephropathy
(deﬁned as any of the criteria above) selected from the ZODIAC study
participants, referred to as the type 2 diabetes population, to compare with the
general population.
Genotyping. Genotyping was performed as described previously (4). In brief,
after PCR ampliﬁcation, fragment analysis was performed on the ABI-3130
analyzer to determine the number of leucine repeats in each allele. The
success rate was on average 95%, and no errors were detected. Genotyping
was performed partially in Leiden and in Mannheim. Some of the samples
were measured in both institutes, and there was a 100% concordance.
Statistical analysis. The baseline characteristics of the groups are presented
as means and SDs or percentages. Continuous variables were tested using the
Student t test and numeric variables using 
2. All groups were tested for
Hardy-Weinberg equilibrium, using a 
2 test.
First, the frequency of the 5-5 homozygous genotype in the respective
diabetic nephropathy groups was compared with the 93 diabetic non-nephrop-
athy control subjects stratiﬁed by sex, to investigate the relevance of the
genotype to disease etiology.
Second, the genotype risk for the population was estimated through
comparison of the diabetic nephropathy groups with population control
subjects. Odds ratios with CIs were calculated. A pooled analysis was
performed to determine the total effect for females and males separately,
combining the three case groups when compared with sex-matched popula-
tion control subjects. The ﬁxed-effects model (inverse variance method) was
used when heterogeneity was P  0.1 (
2) and the random-effects model when
heterogeneity was P  0.1.
Finally, to assess whether the susceptibility for diabetic nephropathy is
independent of susceptibility for type 2 diabetes, we compared the type 2
diabetes population with population control subjects.
The statistical analyses were all performed using SPSS 16.0 and R version
2.9.0.
RESULTS
The baseline characteristics of the three diabetic nephrop-
athy groups are described in Table 1, and comparisons are
made with diabetic non-nephropathy control subjects.
Baseline characteristics did not differ between diabetic
non-nephropathy control subjects and the type 2 diabetes
population, except for diabetes duration (data not shown).
There was no signiﬁcant difference in 5-5 homozygous
genotype frequency between the diabetic non-nephropa-
thy control subjects and the population control subjects
consisting of all patients (P  0.8), all women (P  0.07),
or all men (P  0.13). All cohorts were in the Hardy-
Weinberg equilibrium (found in the online appendix, avail-
able at http://diabetes.diabetesjournals.org/cgi/content/full/
db09-1377/DC1).
Relevance of the 5-5 homozygous genotype to disease
etiology. Overall, the 5-5 homozygous genotype frequency
of the diabetic nephropathy groups did not differ from
the diabetic non-nephropathy control subjects or between
the diabetic nephropathy groups (P  0.2). Women in all
three diabetic nephropathy groups had a signiﬁcantly lower
frequency of the 5-5 homozygous genotype than female
TABLE 1
Baseline characteristics
Diabetic nephropathy groups Type 2 diabetes 15 years
without diabetic
nephropathy 12 3
Total (n) 114 90 66 93
Age (years) 64.0  11.07 73.4  8.40†‡ 66.2  8.97 65.8  11.30
Sex (n (%) male) 64 (56.1) 30 (33.3)†‡ 35 (53.0) 47 (50.5)
Diabetes duration (years) 14.3  8.38† 9.7  9.51†‡ 15.2  10.99† 22.2  6.78
A1C (%) 7.5  1.71 7.5  1.2 — 7.3  1.51
Women
Age (years) 64.2  11.64 72.2  9.09†‡ 67.2  7.57 65.1  12.07
Diabetes duration (years) 14.8  9.24† 9.2  7.77†‡ 15.9  11.83† 22.9  6.50
A1C (%) 8.0  2.08 7.4  1.12 — 7.5  1.65
Men
Age (years) 63.7  10.68 75.9  6.22†‡ 65.3  10.07 66.4  10.60
Diabetes duration (years) 13.9  7.81† 10.7  12.4† 14.7  10.39† 21.6  7.05
A1C (%) 7.2  1.32 7.6  1.38 — 7.6  1.38
†P  0.05 compared with type 2 diabetes 15 years without diabetic nephropathy. ‡P  0.05 compared with either diabetic nephropathy
group 1 or 3. No signiﬁcant differences were seen between group 1 and 3 or between women and men in each of the groups.
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after Bonferroni adjustment for multiple testing. In contrast,
men in all three diabetic nephropathy groups had a higher
frequency of the 5-5 homozygous genotype than male dia-
betic non-nephropathy control subjects.
Genotype risk for the population. No heterogeneity
was detected in women (P  0.64), but heterogeneity was
detected in men (P  0.09). The three diabetic nephropa-
thy groups were pooled for women and men separately,
resulting in a genotype risk of 0.5 (0.30–0.68) in women
and 1.2 (0.77–1.69) in men (Fig. 1).
Speciﬁcity of 5-5 homozygous genotype for diabetic
nephropathy, not type 2 diabetes. The 5-5 homozygous
genotype frequency of both the 562 type 2 diabetic indi-
viduals and the 472 population control subjects are shown
in Table 3, showing similar frequency of the 5-5 homozy-
gous genotype.
DISCUSSION
Our results show a sex speciﬁc effect of the CNDP1
genotype in relation to diabetic nephropathy, suggesting
that the 5-5 homozygous genotype is only protective in
women. The frequency of the 5-5 homozygous genotype
was determined in three independent diabetic nephropa-
thy groups. These groups were compared with two control
groups: patients with type 2 diabetes and a low risk of ever
developing diabetic nephropathy and a sample from the
general population. Compared with the diabetic control
group, the 5-5 homozygous genotype frequency was signif-
icantly lower in women with diabetic nephropathy in all
three cohorts, but not in men. The population control
group serves to estimate the genotype risk for the popu-
lation, showing that women with the 5-5 homozygous
genotype have a twofold reduced risk of ever developing
diabetic nephropathy. Furthermore, this study shows sim-
ilar frequencies of the 5-5 homozygous genotype in a large
type 2 diabetes population and the general population,
underlining that the association with diabetic nephropathy
is independent of a genetic susceptibility for type 2
diabetes.
The 5-5 homozygous genotype leads to lower carnosi-
nase activity compared with the other genotypes (4,6),
leaving more carnosine free to protect the kidney from
oxidative stress. Since men have higher carnosine levels in
their muscle tissue and women have slightly higher serum
carnosinase levels (22), differences in carnosinase activity
due to the different CNDP1 polymorphism may have a
stronger impact in women. Carnosine content in the
muscles of female mice was shown to increase after
testosterone administration, and the increase was 268%
TABLE 2
The relation between 5-5 homozygous genotype and diabetic
nephropathy
Diabetic
nephropathy
groups
Type 2 diabetes 15
years without
diabetic
nephropathy 123
Total
n 114 90 66 93
Frequency 5-5 (%) 28.1 35.6 40.9 43.0
P* 0.03 0.30 0.80
Women
n 50 60 31 46
Frequency 5-5 (%) 24.0 28.3 25.8 58.7
P* 0.001 0.002 0.006
Men
n 64 30 35 47
Frequency 5-5 (%) 31.2 50.0 53.4 27.7
P* 0.62 0.05 0.02
*Compared with type 2 diabetes 15 years without diabetic
nephropathy.
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FIG. 1. The relationship between the 5-5 homozygous CNDP1 genotype
and diabetic nephropathy (DN) in women (A) and men (B) in the three
independent diabetic nephropathy groups and a pooled analysis (total)
compared with population control subjects. The ﬁlled diamonds repre-
sent the odds ratios of the independent diabetic nephropathy groups
and the ﬁlled square represents the pooled odds ratio.
TABLE 3
Comparison between type 2 diabetes population and population
control subjects
Type 2 diabetes
population
Population control
subjects P
Total (n) 562 472
Frequency 5-5 (%) 38.1 41.7 0.23
Women (n) 319 239
Frequency 5-5 (%) 39.5 43.9 0.23
Men (n) 243 233
Frequency 5-5 (%) 36.7 39.5 0.58
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enzyme that synthesizes carnosine, is upregulated by
testosterone. It is possible that this phenomenon plays a
role in diabetic nephropathy, because both carnosine
synthetase (preliminary results) and androgen receptors
are expressed in human kidney (24).
Another explanation for the sex speciﬁc effect found in
this study is that the association between the CNDP1 gene
and diabetic nephropathy is lost in men due to selective
survival by cardiovascular disease. As carnosine has
shown to be protective against oxidative stress and hemo-
dynamic damage (6,12,13), this might also explain its role
in cardiovascular death in diabetic nephropathy patients.
Men with diabetic nephropathy due to type 2 diabetes have
a higher risk for cardiovascular disease than women (25).
Therefore, this might be more prominent in men. Further
support for this theory comes from the ZODIAC study.
Men with a diabetes duration 10 years and the 5-5
homozygous genotype have a signiﬁcantly lower mortality
risk due to cardiovascular disease than patients with 10
leucine repeats in the CNDP1 genotype (data not shown).
We found no difference in cardiovascular death between
the different genotypes in women. These ﬁndings need to
be replicated in an independent study.
The relatively older age of diabetic nephropathy group 2
might inﬂuence the number of subjects with an estimated
glomerular ﬁltration rate 60 ml/min/1.73 m
2. Therefore, a
sensitivity analysis was performed, adopting increasingly
stringent deﬁnitions of diabetic nephropathy. The results
of this analysis support the conclusion that the 5-5 ho-
mozygous genotype is protective in women (see the online
appendix).
The statistical power to detect a similar association in
men as that seen in women ranged from 97 to 100% within
the three diabetic nephropathy groups. Insufﬁcient statis-
tical power therefore does not explain the sex speciﬁc
effect found in this study.
Limitations of this study are that ethnic origin is not
deﬁned by ethnic markers in these Caucasian populations
and that sample sizes are relatively small. We performed a
sensitivity analysis to exclude population stratiﬁcation and
a permutation analysis to rule out that our results are due
to random ﬂuctuation. These analyses support that popu-
lation stratiﬁcation or chance are unlikely to explain the
sex speciﬁc effect found in this study (online appendix).
Another limitation is that the three diabetic nephropathy
groups are compared with the same control group.
In conclusion, this study suggests a sex speciﬁc effect of
the association between the CNDP1 gene and diabetic
nephropathy in three independent patient groups with
diabetic nephropathy due to type 2 diabetes, with women
being protected by the 5-5 homozygous genotype.
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